Human dose equivalent (with the study I posted above as a dosing standard) is 0.8mg/kg.
It might be best to ask about getting a grant for a safety testing study of this chemical. Something simple like a sample of 50 standard rats, some control, test for major markers of health (brain, liver, heart), and see what all-death mortality rates are. Then when we have some mortality results we can think about a group buy, if that is what you were thinking about.
To give people an introduction into this chemical of topic... http://www.ncbi.nlm....pubmed/20919653
Glucosylceramide has a unique and often ambiguous role in mammalian cells. Activation of glucosylceramide synthase, the enzyme that places a glucosyl moiety onto ceramide, is the first pathway-committed step to the production of more complex glycosphingolipids such as lactosylceramide and gangliosides. Alterations in the level of glucosylceramide are noted in cells and tissues in response to cardiovascular disease, diabetes, skin disorders and cancer. Overall, upregulation of glucosylceramide offers cellular protection and primes certain cells for proliferation. However, prolonged overabundance of glucosylceramide is detrimental, as seen in Gaucher disease in humans.
http://www.google.co...tents/US5041441
The injection of glucosylceramide into mice has been shown to produce marked, rapid stimulation of the growth of the liver (which preferentially absorbs the lipid). In the case of mice bearing Ehrlich ascites carcinoma cells, the injection of glucosylceramide resulted in a greater than 50% increase in the number of cancer cells. Recent studies have also indicated that patients with Gaucher's disease, which results from an accumulation of glucosylceramide, have an unexpectedly high incidence of leukemia and other B-cell proliferation disorders.
In accordance with the present invention, cancer cells sensitive to glycosphingolipid metabolism inhibition are treated by contacting the cells with an inhibitor which interferes with the metabolic pathways of glycosphingolipids. The inhibitor can function by blocking the enzymatic synthesis of glycosphingolipids, particularly glucosylceramide and its derivatives, hereinafter collectively referred to as "glucolipids," or by blocking other physiological processing thereof such as their transport.
In addition, the method of the present invention can be used to treat non-malignant conditions caused by cell proliferation such as benign tumors, warts, skin growths and the like. The method of the present invention may also be used to prevent fetal development and terminate undesired pregnancies.
Male mice of the ICR (Swiss Hsd) strain from Harlan--Sprague Dawley (Indianapolis, Ind.) were injected intraperitoneal with saline containing 2×106 Ehrlich ascites tumor cells (EATC) on day 0....
Column (a) indicates the low drug toxicity. Column (b), which shows the change in mean body weight at the end of 10 days, indicates the drug toxicity as evidenced by subnormal weight gain...
A dose response test of D-threo-PDMP showed that the T/C index increased with increasing dosage, as did the percentage of total cure. All animals injected with 25 or 50 mg/kg died at about the same time as the controls, although the drug reduced the chance of early death. The percentages surviving for 60 days were 10%, 20% and 50% for 75, 100, and 125 mg/kg, respectively. After more than 5 months after inoculation, 40% of the two most-heavily dosed mouse groups were still alive and healthy.
So basically D-threo-PDMP has been patented as a potential treatment for some types of cancers, because it also lowers cell proliferation. It didn't seem to effect total mortality, but reduced the risk of early death.